Repligen Corporation

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-06 pm EDT			5-day change	1st Jan Change
168 ^USD	+0.59%		+1.14%	-6.54%

May. 02	UBS Adjusts Price Target on Repligen to $205 From $225, Maintains Buy Rating	MT
May. 01	Repligen's Q1 Adjusted Earnings, Revenue Fall	MT

Repligen Corporation(NasdaqGS:RGEN) added to Russell Midcap Value Index

June 25, 2021 at 12:00 am EDT

Latest news about Repligen Corporation

UBS Adjusts Price Target on Repligen to $205 From $225, Maintains Buy Rating	May. 02	MT
Repligen's Q1 Adjusted Earnings, Revenue Fall	May. 01	MT
Transcript : Repligen Corporation, Q1 2024 Earnings Call, May 01, 2024	May. 01
(RGEN) REPLIGEN CORPORATION Sees Fiscal Year 2024 EPS Range $1.42 - $1.49	May. 01	MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Posts Q1 Revenue $151.3M, vs. Street Est of $150.1M	May. 01	MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Posts Adjusted Q1 EPS $0.28, vs. Street Est of $0.30	May. 01	MT
Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024	May. 01	CI
Repligen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
North American Morning Briefing : Traders Wait for -2-	May. 01	DJ
RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating	Apr. 08	MT
Transcript : Repligen Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-20-2024 03:00 PM	Mar. 20
Repligen Corporation Appoints Maggie A. Pax as Board of Directors	Mar. 19	CI
Repligen Insider Sold Shares Worth $681,348, According to a Recent SEC Filing	Mar. 13	MT
Repligen Insider Sold Shares Worth $3,298,632, According to a Recent SEC Filing	Mar. 12	MT
Repligen Insider Sold Shares Worth $866,204, According to a Recent SEC Filing	Feb. 27	MT
UBS Adjusts Repligen Price Target to $225 From $211, Maintains Buy Rating	Feb. 22	MT
Deutsche Bank Adjusts Repligen Price Target to $180 From $175, Maintains Hold Rating	Feb. 22	MT
RBC Raises Price Target on Repligen to $225 From $200, Keeps Outperform Rating	Feb. 22	MT
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday	Feb. 21	MT
Sector Update: Health Care	Feb. 21	MT
Transcript : Repligen Corporation, Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
Repligen Q4 Adjusted Earnings, Revenue Decline; Issues 2024 Guidance; Shares Fall Premarket	Feb. 21	MT
Sartorius falls - outlook from Repligen disappointed	Feb. 21	DP
(RGEN) REPLIGEN CORPORATION Expects Fiscal Year 2024 EPS Range $1.42 - $1.49	Feb. 21	MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q4 Revenue $155.7M, vs. Street Est of $156.3M	Feb. 21	MT

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Companyâs chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Companyâs TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Repligen Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

167 USD

Average target price

204.2 USD

Spread / Average Target

+22.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
REPLIGEN CORPORATION	-6.54%	9.33B
ABBOTT LABORATORIES	-4.02%	184B
MEDTRONIC PLC	-0.75%	108B
BECTON, DICKINSON AND COMPANY	-2.97%	67.82B
DEXCOM, INC.	+4.48%	51.05B
CENCORA, INC.	+9.09%	44.67B
HOYA CORPORATION	+3.40%	41.78B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.12%	26.78B
WEST PHARMACEUTICAL SERVICES, INC.	+4.10%	26.59B
TERUMO CORPORATION	+15.23%	25.86B

Other Medical Equipment, Supplies & Distribution